A Delhi cardiologist's viral post highlights how daily Rs 20 samosas can lead to a Rs 3 lakh angioplasty, urging preventive ...

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

Background: Little correlation exists between the burden of ischemia and severity of angina in patients with stable coronary artery disease. This placebo-controlled, n-of-1 study investigated the ...

Results from the first randomized controlled trial to directly compare the safety and efficacy of cutting balloon ...

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB ...

LIFE-BTK trial was designed as a superiority trial. The investigators randomly assigned 261 people 2:1 to Esprit or PTA.

Angiodynamics, Inc. (($ANGO)) announced an update on their ongoing clinical study. Study Overview: Angiodynamics, Inc. is conducting a clinical ...

Acotec Scientific Holdings Limited (($DE:7W3)) announced an update on their ongoing clinical study. Study Overview: Acotec Scientific Holdings ...

Boston Scientific also reported findings from the ALLIANCE registry looking at 1,800 Agent patients in Japan. It assessed the ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis ...

SAN FRANCISCO -- The investigational Selution drug-coated balloon (DCB or DEB) edged closer to primetime in percutaneous ...

Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon ('Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release ...